Cost implications and complications of overtreatment of low-risk prostate cancer in the United States
| Autor: | Quoc-Dien Trinh, Andrew S. Hyatt, Jim C. Hu, Ming-Hui Chen, Xiangmei Gu, Powell L. Graham, Jason A. Efstathiou, Paul L. Nguyen, Neil E. Martin, Ayal A. Aizer, Toni K. Choueiri |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty medicine.medical_treatment Disease Logistic regression Prostate cancer Quality of life Cost of Illness Risk Factors Medicine Humans Aged Neoplasm Staging Gynecology Aged 80 and over business.industry Incidence (epidemiology) Incidence Prostatic Neoplasms Odds ratio medicine.disease Combined Modality Therapy United States Oncology Life expectancy Morbidity business Watchful waiting SEER Program |
| Zdroj: | Journal of the National Comprehensive Cancer Network : JNCCN. 13(1) |
| ISSN: | 1540-1413 |
| Popis: | BACKGROUND Evidence-based consensus guidelines recommend only observation for men with low-risk prostate cancer and life expectancy less than 10 years. This report describes the incidence, drivers, cost, and morbidity of overtreatment of low-risk prostate cancer within the United States. METHODS The SEER-Medicare Program was used to identify 11,744 men aged 66 years or older diagnosed with low-risk prostate cancer in 2004 through 2007. Overtreatment of prostate cancer was defined as definitive treatment of a patient with a life expectancy of less than 10 years. Expected survival was estimated using NCCN methodology. Costs were the amount paid by Medicare in years after minus year before diagnosis. Toxicities were relevant Medicare diagnoses/interventions. P values are 2-sided. RESULTS Of 3001 men with low-risk prostate cancer and a life expectancy of less than 10 years, 2011 men (67%) were overtreated. On multivariable logistic regression, overtreated men were more likely to be married (odds ratio [OR], 1.29; 95% CI, 1.05-1.59; P=.02), reside in affluent regions (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|